Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysis.

Cytokine release syndrome (CRS) is a systemic inflammatory syndrome that causes fatal circulatory failure due to hypercytokinemia, and subsequent immune cell hyperactivation caused by therapeutic agents, pathogens, cancers, and autoimmune diseases. In recent years, CRS has emerged as a rare, but significant, immune-related adverse event linked to immune checkpoint inhibitor therapy. Furthermore, several previous studies suggested that damage-associated molecular patterns (DAMPs) could be involved in malignancy-related CRS.

[Activity based costs of different units in a high complexity Chilean hospital].

Background: Hospitals must have management tools that allow them to fulfil all their requirements with the allocated resources.

Aim: To evaluate the number of bed-days according to the discharge diagnosis in a High Complexity Hospital in Chile.

Material And Methods: An activity Based Cost (ABC) calculation was used.